Thermo Fisher Scientific Inc (TMO): Today's Featured Health Services Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Thermo Fisher Scientific ( TMO) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Thermo Fisher Scientific fell 67 cents (-1.1%) to $61.16 on average volume. Throughout the day, 1.5 million shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.9 million shares. The stock ranged in price between $60.98-$61.72 after having opened the day at $61.69 as compared to the previous trading day's close of $61.83. Other companies within the Health Services industry that declined today were: St Jude Medical ( STJ), down 12.2%, Dynatronics Corporation ( DYNT), down 11.1%, Arrhythmia Research Technology ( HRT), down 9.1%, and Heartware International ( HTWR), down 8.8%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $22.12 billion and is part of the health care sector. The company has a P/E ratio of 19.6, above the S&P 500 P/E ratio of 17.7. Shares are up 36.6% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, CombiMatrix Corporation ( CBMX), up 22%, BG Medicine ( BGMD), up 11.5%, NeuroMetrix ( NUROD), up 9.3%, and Bovie Medical Corporation ( BVX), up 7.9%, were all gainers within the health services industry with Boston Scientific ( BSX) being today's featured health services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Jim Cramer: Agilent Technology Has Been One of My Favorites

Secondaries Get Primary Attention; Discerning Market -- Cramer's Top Thoughts

Cramer: Secondary Offerings Get Primary Attention

The Stock Market Is on Fire, Especially in These Sectors: Market Recon

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria